SC
NRIX icon

Stempoint Capital’s Nurix Therapeutics NRIX Stock Holding History

Stempoint Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-315,226
Closed -$4.89M – 101
2026
Q1 		$4.89M Buy
+315,226
New +$5.23M 0.94% 35
2024
Q4 		– Sell
-203,015
Closed -$4.56M – 71
2024
Q3 		$4.56M Sell
203,015
-258
-0.1% -$5.84K 1.37% 23
2024
Q2 		$4.24M Buy
+203,273
New +$3.17M 1.25% 27

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's NRIX Position: Q2 2026 in Review

Stempoint Capital sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 315,226 shares — an estimated $4.89M sold.

Stempoint Capital first reported a position in NRIX in Q2 2024 and held it in 3 quarters. The position peaked at $4.89M in Q1 2026. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Stempoint Capital reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 315,226 Nurix Therapeutics shares in Q2 2026, an estimated $4.89M.
  • Stempoint Capital first reported a position in Nurix Therapeutics in Q2 2024 and held it in 3 quarters.
  • Stempoint Capital's Nurix Therapeutics position peaked at $4.89M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.